In the present study, we developed an assay to evaluate the kinetic binding properties of the unconjugated antisense oligonucleotide (ASO) and lipophilic and hydrophilic ligands conjugated ASOs to mouse and human serum albumin, and lipoproteins using surface plasmon resonance (SPR). The lipophilic ligands conjugated ASOs showed clear affinity to the albumins and lipoproteins, while the unconjugated and hydrophilic ligand conjugated ASOs showed no interaction. The SPR method showed reproducible immobilization of albumins and lipoproteins as ligands on the sensor chip, and reproducible affinity kinetic parameters of interaction of ASOs conjugated with the ligands could be obtained. The kinetic binding data of these ASOs to albumin and lipoproteins by SPR were related with the distributions in the whole liver in mice after administration of these conjugated ASOs. The results demonstrated that our SPR method could be a valuable tool for predicting the mechanism of the properties of delivery of conjugated ASOs to the organs.
Introduction
Antisense oligonucleotides (ASOs) are short synthetic single-strand nucleotide polymers (typically of 7 -30 nucleotides in length) that are designed to specifically hybridize to their target RNA via Watson-Crick base pairing and to prevent expression of the encoded disease-related protein product. ASOs regulate the expression of any disease-related gene whereas small molecule and therapeutic antibody drugs interact with the limited protein targets, which are druggable for small molecule drugs and express outside the cells for therapeutic antibody drugs. To date, two ASOs as drugs have been approved for launch, and clinical trials of ASOs are on-going for the treatment of various diseases such as hyperlipidemia and cancer. 1, 2 As ASOs are mostly hydrophilic and ion charged compounds, they have difficulty accessing the target organs for their beneficial effects. 3 For therapeutic applications, the efficient in vivo delivery of ASOs to their target organs is necessary. Recently, it was reported that ASOs conjugated with cholesterol, tocopherol (vitamin E), and triantennary N-acetyl galactosamine (GalNAc) were especially available for delivery of ASOs to the liver. [4] [5] [6] [7] [8] ASOs conjugated with cholesterol and tocopherol as lipophilic ligands could improve their uptake by the liver via receptor-mediated endocytosis after interaction with albumin and lipoproteins, such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in circulation. The liver takes up most of the LDL via LDL receptor-mediated endocytosis. On the other hand, HDL particles can be either internalized by selective transcytosis or depleted of cholesterol by selective uptake through scavenger receptor class B, type I. [9] [10] [11] [12] [13] [14] [15] [16] GalNAc has a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), and ASO conjugated with GalNAc improves the uptake of the liver via ASGPR-mediated endocytosis. 7 Thus, it is important to evaluate the interactions of ASOs with albumin and lipoproteins in vitro to understand how to improve the uptake of ASOs by target organs. A previous paper reported the binding properties of ASOs to albumin, LDL, and HDL using the radiolabeled ( 32 P) conjugated ASO by gel filtration. 4 As estimating the interaction using radiolabeling might be a troublesome procedure, simpler methods would be desirable for examining the interaction between lipophilic conjugated ASOs and lipoproteins and albumin in vitro.
Surface plasmon resonance (SPR)-based biosensors have been widely applied to study the protein-binding properties of drugs with the aim of gaining insight into their mechanism of action. 17, 18 The use of SPR-based biosensors to study the protein-binding properties of drugs has the advantage of not requiring the presence of labels or chromophores, including the estimation of kinetic analysis. 19 We have already evaluated interactions of various drugs to the target using the SPR biosensor, and demonstrated that it can be used to readily determine the kinetic rate constants and the affinity of ligand interactions. [20] [21] [22] [23] [24] [25] [26] [27] [28] This information can offer important insights into the mechanism of such interactions.
In the present study, we developed an assay to evaluate the interactions of unconjugated ASO and ASOs conjugated with lipophilic ligands and GalNAc to mouse serum albumin, human serum albumin, and lipoproteins using the SPR system. Our final target was to establish a tool to predict the binding properties between the conjugated ASOs and albumin and lipoproteins using the SPR system to find an effective form of delivery conjugation of ASOs.
This report describes an investigation of the binding properties of three conjugated ASOs, including unconjugated ASO, with mouse and human serum albumin, and lipoproteins, LDL, and HDL using SPR technology. The estimated chemical structures of unconjugated ASO and conjugated ASOs synthesized in our laboratory are shown in Fig. 1 . 8, 29 Cholesterol-conjugated ASO (Chol-ASO), tocopherol-conjugated ASO (Toc-ASO), and GalNAc-conjugated ASO (GalNAc-ASO) were considered as the conjugated ASOs, including the unconjugated ASO, which has a high affinity and potency for the apolipoprotein B mRNA. 30 The present assay showed satisfactory reproducibility of immobilization of albumin and lipoprotein onto a sensor chip. The binding properties of unconjugated ASO and conjugated ASOs could be estimated, showing that the unconjugated ASO and GalNAc-ASO could hardly bind to the albumin and lipoprotein. Also the binding kinetics of Chol-ASO and Toc-ASO with respect to the albumin and lipoprotein showed good reproducibility. The comparison between the SPR data and whole liver distributions of these ASOs in mice after administration of each ASO are discussed. 
Experimental

Reagent and chemicals
Unconjugated ASO, 5′-GCattggtatTCA-3′ (gapmer oligonucleotide with locked nucleic acid (capital) and DNA (plain font); all internucleoside linkages are phosphorothiated) was purchased from GeneDesign Inc. (Osaka, Japan), and the conjugated ASOs, synthesized in our laboratory are shown in Fig. 1 . The purities determined by HPLC-UV method were 96.0% for unconjugated ASO, 90.7% for Chol-ASO, 98.3% for Toc-ASO, and 95.7% for GalNAc-ASO. Also the molecular weights determined by high-performance liquid chromatography with tandem mass spectrometric detection were 4324.2 (calculated molecular weight: 4324.6) for unconjugated ASO, 5083.0 for Chol-ASO (calculated molecular weight: 5081.6), 5025.0 for Toc-ASO (calculated molecular weight: 5024.6), and 6244.0 for GalNAc-ASO (calculated molecular weight: 6242.8).
Mouse and human serum albumin, HDL and LDL were purchased from Sigma-Aldrich Co. LLC. (Tokyo, Japan). Distilled water (HLPC grade) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Octylphenyl-polyethylene glycol (IGEPAL CA-630) (IGEPAL) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Concentrated phosphate buffered saline (PBS) and the amine coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N′-(3-diethylaminopropyl)-carbodiimide (EDC) and ethanolamine hydrochloride were purchased from GE Healthcare UK Ltd. (Buckinghamshire, England).
Apparatus
The SPR system used was a BIACORE S51 analytical system, and a CM5 sensor chip was used for immobilization of mouse and human albumin, LDL and HDL (GE Healthcare UK Ltd., Buckinghamshire, England). The running buffer used was PBS for immobilization of the ligands on the chip and for estimation of the interaction of ASOs with mouse and human albumin, LDL and HDL. The regeneration solution was 0.05% IGEPAL in PBS for albumin, and 0.1% IGEPAL in PBS for lipoproteins. All solutions were freshly prepared, degassed and filtered through a 0.22-μm filter.
Immobilization of albumin and lipoproteins on the sensor chip
Mouse and human albumin, HDL, and LDL were immobilized on the CM5 sensor chip surface by the amine coupling method. 28, 31 Briefly, with this coupling method, the carboxymethylated dextran layer on the CM5 sensor chip surface was activated with a 7-min injection of an EDC/NHS mixture after equilibration of the sensor chip surface with PBS buffer at a flow rate of 10 μL/min. Albumin (200 μg/mL) and lipoproteins (100 μg/mL) were coupled by exposing their surfaces to 10 mmol/L sodium acetate, pH 5.0, for 7 min at a flow rate of 10 μL/min. After immobilization of the ligand, unreacted NHS-esters were blocked with 7 min washing with 1 M ethanolamine hydrochloride (pH 8.5).
ASOs binding to albumin and lipoproteins
Assay solutions of ASOs were prepared by being dissolved in PBS from 1 to 8 μM (1, 2, 3, 4, 5, 6, 7 and 8 μmol/L). The assay solution (75 μL, 150 s) was injected over albumin and lipoproteins at a flow rate of 30 μL/min, so as to avoid any limitation by mass transfer. Upon completion of the injection, the buffer flow was continued to allow a dissociation time of 300 s. All binding experiments were carried out at 25 C. To remove ASOs bound to the albumin after dissociation, 20 μL of 0.05% IGEPAL in PBS as a regeneration solvent was injected at a flow rate of 30 μL/min before the next injection of ASO over the sensor chip. To remove ASOs bound to the lipoproteins after dissociation, 20 μL of 0.1% IGEPAL in PBS as a regeneration solvent was injected at a flow rate of 30 μL/min before the next injection of ASO over the sensor chip. The affinity of ASOs for the albumin and lipoproteins was determined from the analysis of a series of response curves collected at eight different concentrations of ASOs injected over each ligand surface using PBS as a running buffer.
Data analysis
The sensorgrams for each ASOs-ligand interaction were analyzed by curve fitting using numerical integration analysis (1 -8 μmol/L). The data were fitted globally by simultaneously fitting the ASOs sensorgrams obtained at eight different concentrations using BIA evaluation software (Ver. 4.1). Evaluation of the association (ka) and dissociation (kd) rate constants was performed by applying linear or nonlinear fitting algorithms to the binding data using the 1:1 Langmuir binding model. This model describes a simple reversible interaction of two molecules in a 1:1 complex. The equilibrium dissociation constants (KD) were obtained from the ratio of the rate constants (kd/ka). The kinetic constants were determined from three different experiments.
Results and Discussion
Repeatability of immobilization of albumins and lipoproteins on the sensor chip
In this SPR study, mouse serum albumin, and human serum albumin, HDL, and LDL were used as albumins and lipoproteins in blood. The immobilization buffer, the concentration of ligands, and the immobilization amounts were optimized, using the CM5 sensor chip via the amino coupling of immobilization of ligands to conduct the desired kinetics binding assay.
The maximum and minimum immobilization amount of ligands were calculated using the molecular weights of ligand and analyte by the following formulas. 31 The minimum immobilization amount (RU) = 200 (RU) × (molecular weight of the ligands/ molecular weight of the analyte) The maximum immobilization amount (RU) = 1000 (RU) × (molecular weight of the ligands/ molecular weight of the analyte) The molecular weight of albumin is approximately 66000, and the suitable immobilization amount of albumin was calculated to be in the range from 2110 to 15260. The target level of immobilization on the CM5 sensor chip was set at approximately 5500 RU. In the case, there was a proportional increase in the response with increases in analytes concentration, indicating that the system had not reached saturation.
Regarding the lipoproteins, the immobilization amount (approximately 6600 RU) of LDL was set similarly as the reported value. 32 In the case, the response of analytes did not increase with increases in analyte concentration, indicating that the system had reached saturation. As the immobilization amount of LDL was increased to approximately 11000 RU, the responses of Cho-ASO in the LDL immobilized sensor chip were investigated. As the result, there was a proportional increase in the response with increases in analytes concentration, indicating that the system had not reached saturation.
The response units (RU) of these ligands immobilized on the sensor chip were measured on three separate experimental days (n = 3), and the average of the response units, standard deviation and relative standard deviation for each ligand type are listed in Table 1 . The relative standard deviation in RU for all ligands was less than 9%, indicating a high level of reproducibility for the immobilization of ligands.
Regeneration of ligand immobilized on the sensor chip
As the ASOs were still bound to the immobilized ligands on the sensor chip after the dissociation phase, regeneration of the sensor chip surface was necessary for the next injection and the procedure of regeneration was optimized. Successful regeneration of the surface chip could be judged by the return of the response to the original baseline; this meant that only the ASOs were removed from the immobilized ligand on the sensor chip. Various solvents, such as acid and alkaline solutions or surfactants for the regeneration, were investigated. As the result, the response returned to the original baseline for the next binding cycle using IGEPAL (Nonidet), which is a surfactant, for the regeneration solution. Figures 2 and 3 show the representative sensorgrams of binding of unconjugated and conjugated ASOs to mouse serum albumin and HDL immobilized on the sensor chip using PBS as a running buffer. Chol-ASO and Toc-ASO showed apparent affinities to serum albumin and lipoprotein, while the unconjugated ASO and GalNAc-ASO had no binding to the ligands. In addition, the sensorgrams of human serum albumin and LDL indicated the same tendency of those of mouse serum albumin and HDL (data not shown). The results indicated that the introduction of the lipophilic ligands to ASOs increased the binding to serum albumin and lipoprotein, compared with those of unconjugated ASO, as reported. 4, 5 Also, GalNAc-ASO, which has a hydrophilic ligand, showed no affinity, as observed for unconjugated ASO. This reason would be due to no increasing lipophilicity of molecular by introduction of the hydrophilic ligand to ASO. Similarly, the unconjugated ASO and GalNAc-ASO had no affinity for human serum protein and LDL. These results also suggest that the SPR method would also be capable of demonstrating the specificity and selectivity of lipophilic ligands conjugated ASO for albumin and lipoproteins.
Binding kinetics of unconjugated and conjugated ASOs to albumins and lipoproteins
There was a distinct increase in the response with increases in Chol-ASO and Toc-ASO concentrations, indicating that the system had not reached saturation. The association (ka) and dissociation (kd) rate constants and the dissociation constant (KD) of Chol-ASO and Toc-ASO estimated by the 1:1 Langmuir binding model are listed in Table 2 . The reproducibility of each parameter of each ASO by repeated assay was good. However, with respect to the affinities of unconjugated ASO and GalNAc-ASO to all the ligands, the kinetics parameters could not be calculated in the case of low affinity and no distinct increase in the response occurred with increases in the analytes concentration.
From the results of repeated kinetic analyses, lower KD values of Chol-ASO and Toc-ASO to the lipoprotein ligands were observed than those for the albumin ligands, indicating that the conjugated ASO showed higher affinity approximately two-folds for the lipoprotein ligand than that for albumin. The binding characteristic obtained by the SPR method was similar to the binding properties of ASOs to albumin, LDL, and HDL using the radiolabeled ( 32 P) conjugated ASO by gel filtrations. 4 The reported binding constants (KD values) of cholesterol conjugated small interfering RNA (siRNA) for LDL and HDL were ~1 × 10 -4 mol/L and ~1.2 × 10 -4 mol/L, respectively. 4 Also the reported KD values of stearoyl-and dodecyl conjugated siRNAs for albumin were ~2 × 10 -4 mol/L. 4 The KD values of lipophilic ligands conjugated ASOs obtained by the SPR method were considerably smaller than those by gel filtrations. 4 A double-strand oligonucleotide was used as conjugated ASO in the report, 4 whereas a single-strand oligonucleotide was used in this study. As a result, we would conclude that the different affinities between the two methods were due in part to the different chemical structures.
As the KD values of mouse and human albumins of two conjugated ASOs were almost the same, no species difference of binding to the albumin was observed in the SPR system. There were also no obvious differences of binding to albumin between Chol-ASO and Toc-ASO in mouse and human. The KD values of binding to the LDL ligands for both Chol-ASO and Toc-ASO were a little lower than those of HDL, indicating that Chol-ASO and Toc-ASO had higher affinities than those of HDL. The affinities of Toc-ASO for the HDL and LDL ligands were a little higher than those of Chol-ASO. The SPR system could provide the affinity, specificity, and selectivity of binding to the albumins and lipoproteins for the conjugated ASOs, compared to unconjugated ASO in vitro.
Comparison of SPR data with liver distribution after administration of ASOs
In a previous study, after administration (1 mg as unconjugated ASO/kg of body weight) of unconjugated ASO and each conjugated ASO to mice, the accumulation of ASO in the whole liver was determined by high-performance liquid chromatography with tandem mass spectrometric detection. 8 The accumulation of ASO in the whole liver was 5% of the dose for unconjugated ASO, 18% of the dose for Chol-ASO, 21% of the dose for Toc-ASO, and 33% of the dose for GalNAc-ASO. The SPR data revealed that Chol-ASO and Toc-ASO had higher affinity for the LDL and HDL ligands than those of unconjugated ASO, indicating that higher distribution of Chol-ASO and Toc-ASO in the liver than that of unconjugated ASO would contribute to the uptake of the liver via lipoprotein receptor-mediated internalization by the complex of conjugated ASO binding to the lipoprotein. Also, the higher affinity of Chol-ASO and Toc-ASO to albumin could promote the retention of these ASOs in blood, resulting that the pharmacokinetics properties in the whole body would be improved and followed by the distribution in the liver would be contributed.
On the other hand, the distribution of GalNAc-ASO in the whole liver was 33% of the dose and was the highest among the ASOs, although the SPR data showed no binding to the lipoproteins, in contrast to Chol-ASO and Toc-ASO. The results would presume that GalNAc-ASO might be taken into the liver mainly via ASGPR-mediated endocytosis, not via binding to albumin and lipoproteins in the blood. 7 These results indicate that the SPR method could be also a valuable tool for understanding the mechanism of the properties of delivery of conjugated ASOs to the organs.
Conclusions
We developed an SPR assay to evaluate the kinetics binding properties of unconjugated ASO and lipophilic and hydrophilic ligands conjugated ASOs to mouse and human serum, and lipoproteins, LDL and HDL. The SPR method we developed showed reproducible immobilization of albumins and lipoproteins as ligands on a sensor chip, and reproducible affinity kinetics parameters of unconjugated ASO and ligands conjugated ASOs could be obtained. Unconjugated ASO and hydrophilic ligand, triantennary N-acetyl galactosamine conjugated ASOs showed no binding to the albumins and lipoproteins, while the lipophilic ligands, cholesterol and tocopherol conjugated ASOs had affinity for the ligands. There were also no obvious differences of binding to albumin between Chol-ASO and Toc-ASO in mice and humans. The affinities of cholesterol and tocopherol conjugated ASOs to the lipoproteins were higher than those of serum albumin. To the best of our knowledge, this is the first report of an SPR study of unconjugated and conjugated ASOs with albumin and lipoprotein interactions. This newly developed SPR system could provide the affinity, specificity, and selectivity of binding to the albumins and lipoproteins for the conjugated ASOs, compared to unconjugated ASO in vitro. In addition, the kinetic binding data of these ASOs to the albumin, LDL, and HDL by SPR were related with these distributions in the whole liver in mice after administration of each ASO. Our SPR method could also be a valuable tool for understanding the mechanism of the properties of delivery of the conjugated ASOs to the organs. 
